In recent years, the peptide drug discovery field has shown a high level of dynamism, with hundreds of academic groups working on this topic, the creation of new peptide-focused companies, and the consolidation of peptide business by so-called big pharma \[[@B1-molecules-25-02293],[@B2-molecules-25-02293],[@B3-molecules-25-02293],[@B4-molecules-25-02293]\].

In the last five years (2015--2019), the U.S. Food Drug Administration (FDA) have authorized a total of 208 new drugs (150 new chemical entities and 58 biologics) \[[@B5-molecules-25-02293],[@B6-molecules-25-02293]\], 15 of which were peptides or peptide-containing molecules ([Table 1](#molecules-25-02293-t001){ref-type="table"}), which account for 7% of the total number of drugs \[[@B4-molecules-25-02293],[@B7-molecules-25-02293]\]. This is a rather impressive number, if we consider the efforts of the pharmaceutical industry in peptides in comparison to small molecules (in the context of this work, a peptide is defined as a compound that contains two or more amino acids linked by an amide (peptide) bond and that can be synthesized chemically).

The chemical structure and medical indication of the active principle ingredient of these drugs show an excellent representation of the diversity of the peptide world.

From a chemical structure perspective, it is possible to find small peptides (Ninlar^®^, Macrilen^®^); medium-sized peptides (Giapreza^®^, Scenesse^®^); homodetic (through amide bonds) cyclic peptides (Vyleesi^®^); intra- and intermolecular disulfide-containing peptides (Parsabiv^®^, containing almost exclusively D-amino acids; Trulance^®^); large peptides (Tymlos^®^, Lixisenatide^®^), which in some cases are branched (Ozempic^®^, Tresiba^®^); and peptides containing radionuclides \[Lutathera^®^, 68Ga DOTA-TOC (^68^Ga-labeled 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-D-Phe1-Tyr3-octreotide)\]. In the case of the two antibody drug conjugates (ADC) PADCEV^®^ and Polivy^®^, the payload is the peptide monomethyl auristatin E (MMAE), a synthetic analog of the marine natural peptide dolastatin 10. MMAE is also the drug contained in Adcetris^®^, which was approved by the FDA in 2011. Of the seven FDA-approved ADCs to date, three contain a peptide. Moreover, PADCEV^®^ and Polivy^®^ contain the dipeptide Val-Cit as a linker. Another peptide-based linker, Gly-Gly-Phe-Gly, is present in the ADC Enhertu^®^, which was authorized by the FDA in 2019.

Oncology, with five drugs (two radio peptides and two ADCs), metabolism (three), and endocrinology (two) are the most frequent medical indications for peptides. However, cardiovascular conditions, gastroenterology, bone diseases, dermatology, and sexual dysfunction are also targeted by peptides.

Of note, between 2015 and 2019, several of the new peptide-based drugs accepted by the FDA came about from the efforts of academic groups. This highlights the importance of fostering solid and efficient cooperation channels between academia and industry with the aim to maintain and improve the well-being of society.

In addition to the use of peptides as drugs or in diagnostics, these molecules are playing an increasingly important role as drug delivery systems and as the base for new biomaterials with broad potential applications in medicine.

This analysis supports the strength of peptides in the medicinal field. In this context, we have decided to publish a Special Issue in Molecules, termed "Peptide Therapeutics 2.0", which contains excellent quality research articles and comprehensive reviews on peptides. It is hoped that some of the peptides introduced herein will reach the market in the coming years.
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###### 

Peptide-based drugs approved by the Food Drug Administration (FDA) (2015--2019) \[[@B3-molecules-25-02293],[@B4-molecules-25-02293],[@B5-molecules-25-02293],[@B6-molecules-25-02293]\].

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Year   Active Ingredient\                   Indication                           Features
         Trade Name                                                                
  ------ ------------------------------------ ------------------------------------ --------------------------------------------------------------------------------------------
  2015   Insulin degludec\                    Diabetes                             Modified insulin with an aa deletion and a hexadecanedioic acid via γ-Glu at the Lys (B29)
         Tresiba^®^                                                                

  2015   Ixazomib\                            Multiple myeloma                     *N-*Acylated, *C-*boronic acid dipeptide
         Ninlar^®^                                                                 

  2016   Adlyxin\                             Diabetes                             44 aa GLP-1 peptide with (Lys)~6~ at the *C*-terminal
         Lixisenatide^®^                                                           

  2017   Abaloparatide\                       Osteoporosis                         34 aa analog of parathyroid hormone-related protein
         Tymlos^®^                                                                 

  2017   Angiotensin II\                      Hypotension                          Natural octapeptide
         Giapreza^®^                                                               

  2017   Etelcalcetide\                       Hyperparathyroidism                  Ac-DCys-DAla-(DArg)~3~-DAla-DArg-NH~2~ linked to L-Cys through a disulfide bridge
         Parsabiv^®^                                                               

  2017   Macimorelin\                         Growth hormone deficiency            Pseudotripeptide *N-*formylated
         Macrilen^®^                                                               

  2017   Plecanatide\                         Chronic idiopathic constipation      16 aa with two disulfides
         Trulance^®^                                                               

  2017   Semaglutide\                         Diabetes                             GLP-1 peptide (31 aa in the chain) with hexadecanedioic acid via γ-Glu and mini PEG at Lys
         Ozempic^®^                                                                

  2018   177Lu DOTA-TATE\                     Neuroendocrine tumors, theranostic   177Lu chelated by DOTA bound to Tyr3-octreotate
         Lutathera^®^                                                              

  2019   68Ga DOTA-TOC                        Neuroendocrine tumors, diagnostic    68Ga chelated by DOTA bound to Tyr3-octreotide

  2019   Afamelanotide\                       Skin damage and pain                 13 aa lineal peptide analog of α-MSH
         Scenesse^®^                                                               

  2019   Bremelanotide\                       Women hypoactive sexual desire       7 aa cyclic peptide analog of α-MSH
         Vyleesi^®^                                                                

  2019   Enfortumab Vedotin-Ejfv PADCEV^®^    Cancers expressing Nectin-4          ADC with a synthetic analog of the marine natural peptide dolastatin 10

  2019   Polatuzumab Vedotin-Piiq Polivy^®^   Diffuse large B-cell lymphoma        ADC with a synthetic analog of dolastatin 10 (5-residue peptide alcohol)
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
